Qinghui Lianuo's Allogeneic B7H3-Targeted CAR-γδ T Cell Therapy QH104 to Be Featured in Oral Presentation at ESMO 2024

Jul 20, 2024 07:57 CST Updated 07:57

Unicet Biotech

Developer of γδ T Cell Therapeutics

Recently, a company within the Zhongguan Village Life Science ParkQinghui LianuoAnnouncement, CompanySelf-developed allogeneic universal CAR-γδ T cell drug QH104 targeting B7H3The latest clinical trial results have been selected for the 2024 European Society for Medical Oncology (ESMO) Annual Meeting and will be presented in detail as a preferred oral report.

Estimated reading time: 3 minutes

Report No.:4420

Date:September 13, 2024, 14:20-14:30 (CEST)

Research Field:Central Nervous System Tumors

English Title:A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma

Principal Investigator:Professor Yulun Huang, Dushu Lake Hospital Affiliated to Soochow University

This study is a first-in-human clinical trial of a universal B7H3 CAR-γδ T cell (QH104) therapy for recurrent glioblastoma (rGBM), led by Professor Huang Yulun from the Department of Neurosurgery at Dushu Lake Hospital, affiliated with Soochow University. The primary objective of this study is to evaluate the safety and tolerability of intrathecal infusion of QH104 in treating B7H3-positive rGBM, while the secondary objectives are to assess the pharmacokinetic profile and preliminary efficacy of the infused cells. The results indicate that QH104 demonstrates favorable safety, and the observed clinical benefits in the rGBM patient population support further clinical development.

The 2024 European Society for Medical Oncology (2024 ESMO) Congress will be held in Barcelona, Spain, from September 13 to 17 local time. As one of the most influential oncology conferences globally, the ESMO Congress is dedicated to finding the most effective cancer treatment solutions available today. Each year, it attracts top international experts and groups from various disciplines who actively share and analyze the latest cutting-edge oncology research achievements and cancer treatment technologies worldwide. Only a few high-quality original studies are selected for the preferred oral presentations annually.

About QH104

QH104 is an allogeneic universal CAR-γδ T cell therapy independently developed by Qinghui Lianuo that targets B7H3. This product utilizes a unique γδ T cell engineering strategy, enabling it to simultaneously recognize tumor surface antigens and specific metabolites, demonstrating promising therapeutic effects against various tumors in preclinical studies. Additionally, this product is an off-the-shelf universal cell therapy, significantly reducing production costs compared to autologous cell therapies, with good clinical accessibility.

About Qinghui Lianuo

Qinghui Lianuo was founded in September 2018,Led by Professor Yonghui Zhang's team from the School of Pharmaceutical Sciences, Tsinghua University, is a company based inNovel Immune Cells (γδ T Cells)A company developing innovative immunotherapeutics, committed to fully exploring the potential of γδ T-cell/BTN immune mechanisms in the treatment of cancer and infectious diseases. Currently, the company has established a multi-pipeline layout in allogeneic off-the-shelf cell therapies, small molecule drugs targeting novel pathways, and antibody drugs for new targets.

Source: Qinghui Lianuo Official Website

In April 2024, a project was initiated by the GCP Center of the Cancer Hospital, Chinese Academy of Medical Sciences, in collaboration with Qinghui Lienal.Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastasis in Solid Tumors(IIT Study) Officially Launched.